deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT02598596

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE)

Sponsor: Ampel BioSolutions, LLC

Conditions Gout
Interventions Azathioprine Pegloticase
Updated 13 times since 2017 Last updated: Oct 7, 2021 Started: Dec 31, 2015 Primary completion: Apr 13, 2020 Completion: Apr 27, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02598596, this PHASE2 trial focuses on Gout and remains completed. Sponsored by Ampel BioSolutions, LLC, it has been updated 13 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Oct 2017 · 5 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Aug 2020 · 18 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Feb 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

  3. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  4. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  5. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  6. May 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  7. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ampel BioSolutions, LLC
  • IND 2 Results LLC
Data source: Ampel BioSolutions, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Cleveland, United States , Detroit, United States , Duncansville, United States , Eagan, United States , Huntsville, United States , Orangeburg, United States , Orchard Park, United States , The Bronx, United States , Wheaton, United States and 1 more location